TSX Penny Stocks Under CA$900M Market Cap: 3 Intriguing Picks

As newly announced tariffs and inflation concerns continue to drive market volatility, Canadian investors are navigating a landscape where economic growth could face headwinds. Amidst these challenges, penny stocks—often representing smaller or newer companies—remain an intriguing area for potential investment. While the term "penny stocks" may seem outdated, these securities can offer opportunities for growth at lower price points when backed by strong financials and solid fundamentals.

Top 10 Penny Stocks In Canada

Click here to see the full list of 925 stocks from our TSX Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Discovery Silver (TSX:DSV)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Discovery Silver Corp. is a mineral exploration company focused on the exploration and development of polymetallic mineral deposits, with a market cap of CA$832.86 million.

Operations: Discovery Silver Corp. does not report any revenue segments as it is primarily engaged in mineral exploration and development activities.

Market Cap: CA$832.86M

Discovery Silver Corp., with a market cap of CA$832.86 million, is a pre-revenue entity focused on mineral exploration and development. Despite its unprofitable status and increasing losses, the company maintains a stable cash runway for 12 months and has no debt. Recent strategic moves include filing a CA$500 million Shelf Registration and acquiring the Porcupine Complex in Ontario. Additionally, it was added to the S&P/TSX Global Mining Index, which could enhance visibility among investors. However, potential investors should consider the company's reliance on capital raises for funding operations as it continues to develop its projects without significant revenue streams yet.

• Take a closer look at Discovery Silver's potential here in our financial health report.
• Gain insights into Discovery Silver's future direction by reviewing our growth report.

RTG Mining (TSX:RTG)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: RTG Mining Inc. is involved in the exploration and development of mineral properties, with a market cap of CA$33.86 million.

Operations: RTG Mining Inc. currently does not report any revenue segments.

Market Cap: CA$33.86M

RTG Mining Inc., with a market cap of CA$33.86 million, is pre-revenue and unprofitable, reporting a net loss of US$5.15 million for 2024. The company recently raised A$19.58 million through a follow-on equity offering to bolster its cash runway, which was previously sufficient for only two months based on free cash flow estimates. While RTG is debt-free and has an experienced management team with an average tenure of 7.4 years, it faces challenges such as high share price volatility and insider selling over the past three months, highlighting potential risks for investors in this speculative sector.

• Click here and access our complete financial health analysis report to understand the dynamics of RTG Mining.
• Examine RTG Mining's past performance report to understand how it has performed in prior years.

NervGen Pharma (TSXV:NGEN)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: NervGen Pharma Corp. focuses on discovering, developing, and commercializing pharmaceutical treatments for nervous system damage, with a market cap of CA$185.06 million.

Operations: NervGen Pharma Corp. does not currently report any revenue segments.

Market Cap: CA$185.06M

NervGen Pharma Corp., with a market cap of CA$185.06 million, is pre-revenue and focuses on developing treatments for nervous system damage. The company recently advanced its Phase 1b/2a trial for NVG-291 targeting spinal cord injuries, enrolling participants in both chronic and subacute cohorts. This trial has received Fast Track designation from the FDA and partial funding from Wings for Life, indicating potential but speculative progress in its pipeline. Despite being debt-free with short-term assets exceeding liabilities, NervGen faces challenges such as unprofitability and limited cash runway projected at ten months without further capital infusion.

• Dive into the specifics of NervGen Pharma here with our thorough balance sheet health report.
• Learn about NervGen Pharma's historical performance here.

Seize The Opportunity

• Reveal the 925 hidden gems among our TSX Penny Stocks screener with a single click here.
• Interested In Other Possibilities? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com